Nanocovax receives hundreds of millions of dollars in funding for vaccine production

The grant aims to promote the production of Vietnam’s first Covid-19 vaccine, ensuring the completion of the vaccination program for people this year.
Nanocovax project of Nanogen Company has just received a grant of up to hundreds of millions of USD from a domestic private corporation, to promote Vietnam’s vaccine trial phase 3, the final phase of testing to approved for general use.

At the same time, the grant helps to urgently invest in the production system of materials and equipment to ensure the supply of a sufficient number of necessary vaccines, supplemented with the amount of imported vaccines, towards the completion of the Covid-19 vaccination program. -19 for the people of Vietnam right this year. Test injection of Nanocovax vaccine phase 1 at the Military Medical Academy. Photo: Viet Linh. In phase 3, the Nanocovax vaccine will be tested in multi-centers at domestic facilities with about 13,000 volunteers. In the North, there are Military Medical Academy and Hung Yen, in the South, there are Pasteur Institutes in Ho Chi Minh City and Long An. Phase 3 is divided into several sub-phases, first injecting 800 registered volunteers, then continuing to recruit more. The optimal dose chosen for phase 3 is 25 mcg. Through the study, all 3 dose groups of 25 mcg, 50 mcg and 75 mcg produced equivalent immunity, due to the equal effectiveness, the Ethics Committee chose the lowest dose for production, saving raw materials. If all goes well, by the end of September, phase 3 testing will be complete. At that time, Vietnam can produce the first Covid-19 vaccine. Exchange with Zing Mr. Ho Nhan, founder and general director of Nanogen Company, did not comment or disclose more about this information. He said the company has stocked up enough materials to produce a vaccine right after the third phase of testing is completed. The company said that if it goes well, it can produce 100 million doses this year. Nanocovax vaccine is Vietnam’s first Covid-19 vaccine that is allowed to be tested in clinical trials, manufactured by Nanogen Company based on recombinant protein technology. The phase 1 clinical trial took place from December 17, 2020, to the end of April completed the phase 2 trial on 560 volunteers, expanding the audience from 18 to over 60 years old, of which one the number of people with underlying diseases such as hypertension, dyslipidemia, diabetes, grade 1 cardiovascular disease… are not too severe. Besides Nanocovax, the second domestic vaccine being tested is Covivac of IVAC Company, which has now completed phase 1 injection.